491833-29-5

Basic information

• Product Name: Eliglustat
• Synonyms: Eliglustat;Genz 99067;N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]-octanamide;N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1- pyrrolidinyl)-2-propanyl]octanamide;Eliglustat(Genz-99067)
• CAS NO: 491833-29-5
• Molecular Formula: C₂₃H₃₆N₂O₄
• Molecular Weight: 404.54294
• Mol File: 491833-29-5.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 615.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.123±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 13.45±0.20(Predicted)
• CAS DataBase Reference: Eliglustat(CAS DataBase Reference)
• NIST Chemistry Reference: Eliglustat(491833-29-5)
• EPA Substance Registry System: Eliglustat(491833-29-5)

Safety Data

• Hazardous Substances Data: 491833-29-5(Hazardous Substances Data)

Usage

Description

Eliglustat is a carboxamide compound that acts as a specific and potent inhibitor of glucosylceramide synthase. It is derived from the formal condensation of the carboxy group of octanoic acid with the primary amino group of a specific compound. Eliglustat is primarily used for the treatment of Gaucher's disease and has shown effectiveness in inhibiting the enzyme responsible for the accumulation of glucosylceramide in the body.

Uses

Used in Pharmaceutical Industry:
Eliglustat is used as a therapeutic agent for the treatment of Gaucher's disease. It works by inhibiting the enzyme glucosylceramide synthase, which is responsible for the synthesis of glucosylceramide. This inhibition helps to reduce the accumulation of glucosylceramide in the body, providing relief from the symptoms associated with Gaucher's disease.
Used in Research and Development:
Eliglustat is also used as a research tool in the study of glucosylceramide synthase and its role in various cellular processes. It can be employed to investigate the effects of inhibiting this enzyme on cellular functions and to develop a better understanding of the underlying mechanisms of Gaucher's disease and other related conditions.

Upstream product

• 125244-73-7 2-nitro-1-(1-pyrrolidinyl)ethanone 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 74053-94-4 ethyl 3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-oxopropanoate 
• 4629-54-3 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone 
• 35970-31-1 2-amino-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethan-1-one hydrochloride 
• 2879-20-1 1,4-benzodioxan-6-yl methyl ketone 
• 502483-57-0 tert-butyl ((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)carbamate 
• 491833-28-4 (1R,2R)-2-amino-1-(2,3-dihydrobenzo[β][1,4]dioxin-6-yl)-3-pyrrolidin-1-yl-propan-1-ol 

Relevant articles and documents

Preparation method of gaucher disease treatment drug eliglustat

The invention relates to a preparation method of a gaucher disease treatment drug eliglustat. The preparation method comprises the following steps: using S-isopropyl-2-oxazolidinone as a raw material,carrying out a condensation reaction, a bromination reaction, a substitution reaction, a hydrolysis reaction, a condensation reaction and a reduction reaction to obtain eliglustat, and carrying out salt forming and two-step purification on the eliglustat to obtain high-purity eliglustat tartrate. According to the method, the chiral center is completely synthesized from the starting material, so that the reaction steps are reduced, the production period is shortened, the synthesis efficiency of the chiral center is improved, the yield of the final product is improved, the salt forming steps are optimized in detail, and the qualified quality control of the bulk drug is ensured.

Eliglustat intermediate and preparation method thereof

The invention relates to an eliglustat intermediate and a preparation method thereof, and provides a series of intermediate compounds for preparing eliglustat, and a preparation method of the intermediates. With the method provided by the invention, raw materials and a transition metal catalyst are subjected to an asymmetric hydrogenation reaction on under certain conditions, and then a series ofreactions are performed to prepare eliglustat. The method provided by the invention is simple and controllable in reaction conditions and easy for industrial production.

STABLE N-((1R,2R)-1-(2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL)-1-HYDROXY-3-(PYRROLIDIN-1-YL)PROPAN-2-YL) OCTANAMIDE (2R,3R)-2,3-DIHYDROXYSUCCINATE PREMIX AND PROCESS FOR PREPARATION THEREOF

The present invention related to stable N-((1R, 2R)-1-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)- 1-hydroxy-3- (pyrrolidin-1-yl)propan-2-yl) octanamide (2R,3R)- 2,3-dihydroxysuccinate premix of formula (Ia) and its process for preparation thereof. The present invention also related to process for the preparation of N-((1R, 2R)-1-(2,3-dihydrobenzo[b][1,4] dioxin-6- yl)-1-hydroxy-3- (pyrrolidin-1-yl) propan-2-yl) octanamide of formula (I) and pharmaceutically acceptable salts.